Q: GUD. At the end of the day, the stock is still pretty low ($7.56). Would you advise letting it run, and await better stock price ? I bought the stock at $10.15. Will it come back at that price, with patience ?
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: I have a question about two companies.
11.6% of XX shares were acquired by Campbell at 39.5 cents. The stock was halted and it dropped after the halt was removed to around 33 cents. Do you think there is something cooking or it is just pure speculation. Would you recommend buying If already owned.
CHH dropped a lot due to CEO resignation and the shares dropped. I already had some shares at 63 cents and I bought more at 53. Is this a good company for one year time frame. Thanks
11.6% of XX shares were acquired by Campbell at 39.5 cents. The stock was halted and it dropped after the halt was removed to around 33 cents. Do you think there is something cooking or it is just pure speculation. Would you recommend buying If already owned.
CHH dropped a lot due to CEO resignation and the shares dropped. I already had some shares at 63 cents and I bought more at 53. Is this a good company for one year time frame. Thanks
Q: Hello,
Any thoughts about Charles River Labs? Why did the stock drop in the last month?
Thanks!
Derek
Any thoughts about Charles River Labs? Why did the stock drop in the last month?
Thanks!
Derek
Q: Is this a decent tax loss candidate for purchase?
Q: Rht has had a very big move lately. It appears they are adding about 2000 patients per month, 6000 total by 2017 year end and 30000 2018. I listened to the conference call and found it very compelling on all fronts. Can you take a new look at it please.
Regards
Regards
Q: Any view on this one?
Q: Your outlook on EXE please. Do you like it, would you add new money today.
Q: my pharma bio is very thin Savaria in Canada and Pfizer inU.S.
However I am hesitant to add holdings.
does switching out of Pfizer to Wallgreen (a top pic recentlyin BNN )or J&J add value
However I am hesitant to add holdings.
does switching out of Pfizer to Wallgreen (a top pic recentlyin BNN )or J&J add value
Q: Greetings 5i,
VRX seems to have rallied since it reported. Mgt looks to be doing a good job in reducing debt and providing transparency. They also offered notes I believe mid November reducing near term debt. I know you are cautious re: VRX however what additionally would be needed to endorse this company? It seems to be racing away as we sit and hope for more improvements.
Cheers!
VRX seems to have rallied since it reported. Mgt looks to be doing a good job in reducing debt and providing transparency. They also offered notes I believe mid November reducing near term debt. I know you are cautious re: VRX however what additionally would be needed to endorse this company? It seems to be racing away as we sit and hope for more improvements.
Cheers!
Q: I would appreciate your analysis/comments on the recent q results of this company.
-
Canopy Growth Corporation (WEED $1.73)
-
Aphria Inc. (APHA $16.55)
-
Aurora Cannabis Inc. (ACB $5.89)
-
CanniMed Therapeutics Inc. (CMED $27.00)
Q: During the merger period in the Canadian Cannabis Industry, who do you see as the potential winners?
-
Knight Therapeutics Inc. (GUD $5.98)
-
Savaria Corporation (SIS $23.86)
-
CanniMed Therapeutics Inc. (CMED $27.00)
Q: Hello Peter and Ryan,
Cannimed has provided the following press release
http://www.businesswire.com/news/home/20171130006170/en/Actions-Words-Aurora-CEO%E2%80%99s-Actions-Reveal-Aurora
which basically illustrates insider selling by Aurora executives on November 28, 2017 while Aurora is in the midst of a takeover of Cannimed.
How is this recent information on insider selling obtained? I am thinking of adding to Savaria Corp giving it total of 5 percent weight and Knight to 7 percent given its recent weakness. Any comments please. Thanks again
Cannimed has provided the following press release
http://www.businesswire.com/news/home/20171130006170/en/Actions-Words-Aurora-CEO%E2%80%99s-Actions-Reveal-Aurora
which basically illustrates insider selling by Aurora executives on November 28, 2017 while Aurora is in the midst of a takeover of Cannimed.
How is this recent information on insider selling obtained? I am thinking of adding to Savaria Corp giving it total of 5 percent weight and Knight to 7 percent given its recent weakness. Any comments please. Thanks again
Q: You had responded to a previous member question about Neptune Tech waiting for its Investor communications on Nov 28th. I see it has sold the Krill Oil business and is now into cannabis derivative products. The current p/e is stated as 5.5 x and there was quite a bit of insider buying (albeit at lower prices). Has your opinion changed as to whether this would be a good speculative purchase for me?
Thanks,
Brian
Thanks,
Brian
Q: Would these companies be timely investments at current levels?
Thanks Team!
Thanks Team!
Q: Could you please comment on Bruker Corporation in US. Growth, debt, valuation.
Would you buy it today?
Thanks,
Milan
Would you buy it today?
Thanks,
Milan
Q: Hello Folks:
Could you please give me your view on Merck and Company (which along with Smith- Kline) has had problems executing new drugs (eg. lung cancer medications) in their pipelines. I also have previously owned Gilead, whose new HIV drug was reduced in value because of government pricing restrictions. My other health care equities are Johnson and Johnson and Knight Therapeutics. Do you think there are better health industry options (with decent dividends and growth potential) in the U.S. other than companies such as Merck, Gilead etc. or should one look to another sector.
Thanks for everything
brian
Could you please give me your view on Merck and Company (which along with Smith- Kline) has had problems executing new drugs (eg. lung cancer medications) in their pipelines. I also have previously owned Gilead, whose new HIV drug was reduced in value because of government pricing restrictions. My other health care equities are Johnson and Johnson and Knight Therapeutics. Do you think there are better health industry options (with decent dividends and growth potential) in the U.S. other than companies such as Merck, Gilead etc. or should one look to another sector.
Thanks for everything
brian
Q: If confidence is high on GUD, am I better to buy some July 2018 calls?
Q: Good Morning, while reading IBD I came across the company ABMD Abiomed and it peaked my interest. Could I get your opinion knowing the US is not your focus area. Thank you
Q: The price of ASP has increased around 200% in the last few days. Is there any reason for this increase and would you think it is a good buy?
Thank you
Thank you
Q: Is there an ETF that covers the cannibis companies?